List view / Grid view
15 March 2016 | By Victoria White
The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
15 March 2016 | By Victoria White
A real-world study showed use of Invokana (canagliflozin) is associated with significantly greater improvements in blood glucose control compared to DPP-4 inhibitors...
14 March 2016 | By Black Swan Analysis
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month...
14 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will be on Stand 12 at the upcoming Med-Tech Innovation Expo at the Ricoh Arena in Coventry, April 20-21...
14 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will exhibit on Stand 307 at Making Pharmaceuticals, April 26-27...
14 March 2016 | By Victoria White
In a study, abiraterone acetate plus prednisone provided an 11.8 months overall survival benefit compared to an active control of placebo plus prednisone...
14 March 2016 | By Victoria White
Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo...
14 March 2016 | By Victoria White
The European Medicines Agency's review follows concerns over serious adverse events in ongoing clinical trials of Zydelig (idelalisib)...
14 March 2016 | By Victoria White
The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia...
14 March 2016 | By Victoria White
The approval is based on a Phase I study that included 50 patients with ROS1-positive metastatic NSCLC treated with 250 mg of Pfizer's Xalkori (crizotinib) orally twice daily...
The Thermo Fisher Scientific™ global bio/pharma tour is an opportunity to collaborate and network directly with experts in technology innovation...
11 March 2016 | By Victoria White
A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.…
11 March 2016 | By Victoria White
A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA...
10 March 2016 | By Victoria White
Teva is to support IVF-Worldwide with a research grant to improve knowledge of fertility preservation protocols for women diagnosed with cancer...
10 March 2016 | By Victoria White
EAF experts have issued a collaborative letter to over 350 European decision makers celebrating the year one progress of the Brussels Declaration on ADPKD...
